INS and Hypoglycemia: Subsequently, the DEVOTE trial demonstrated that, among insulin-naïve T2D patients at high risk for cardiovascular events, degludec was noninferior to glargine with respect to the incidence of MACE, but was associated with significantly lower rates of severe hypoglycemia [6].